Alkem Lab jumps 4.5% as it launches Favipiravir drug to treat Covid-19
Alkem Laboratories has launched Favipiravir under the brand name 'Alfluenza' in India for the management of mild to moderate cases of Covid-1906-08-2020
06-08-2020
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to intimate you that Alkem Laboratories Limited (the 'Company') has launched Favipiravir in India under the brand name 'Alfluenza' for the treatment of mild to moderate COVID-19. Favipiravir has received authorization from the Drug Controller General of India (DCGI) for restricted emergency use in India. A press release in this regards is enclosed herewith. Kindly take the same on record.05-08-2020
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a conference call to discuss the Q1FY21 financial results will be held on Friday, 07th August, 2020 at 04.45 pm. Please find attached herewith the conference call details. Kindly take note of the same.28-07-2020
Alkem Laboratories Ltd - 539523 - Board Meeting Intimation for Notice Of Meeting Of The Board Of Directors Of The Company Scheduled To Be Held On 07Th August, 2020.
Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2020 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2020. Kindly take note of the same.27-07-2020
Alkem Laboratories Ltd - 539523 - Compliance Status Certificate (in terms of SEBI Exemption Order) for the financial year ended March 31, 2020
Compliance Status Certificate (in terms of SEBI Exemption Order) for the financial year ended March 31, 2020.23-07-2020
Why Alkem Laboratories is a good buy
Strong domestic presence in acute segment, steadily growing US business are positives19-07-2020
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 and 47 read alongwith Schedule Ill of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulation"}, please find enclosed herewith a copy of advertisement published in today''s Newspapers viz. Business Standard (English) and Lakshadweep (Marathi) informing about completion of dispatch of Notice of the 46th AGM alongwith Annual Report for the financial year 2019-20 and availability of e-voting facility available to the shareholders. The same is also available on the website of the Company at www.alkemlabs.com. Kindly take the same on record.17-07-2020
Alkem Laboratories Ltd - 539523 - Reg. 34 (1) Annual Report
Please find enclosed herewith the Notice of the 46th Annual General Meeting of the Company scheduled to be held on Tuesday, 18th August, 2020 at 11.00 a.m. through Video Conferencing (VC)/ Other Audio Visual Means (OAVM) alongwith the Annual Report for the financial year 2019-2020. The same is also available on the website of the Company at www.alkemlabs.com Kindly take the same on record.16-07-2020
Alkem Laboratories Ltd - 539523 - Shareholding for the Period Ended June 30, 2020
Alkem Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here15-07-2020
Alkem Labs, Torrent Pharma expected to outperform, build long positions
On the candlestick front, Alkem Labs has witnessed a 'Rising Three' formation on its daily scale which indicates the upmove to remain consistent intact.15-07-2020